NCT02941549 - Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

January 2, 2019

Study Completion Date

March 4, 2019

Conditions

Non Alcoholic Fatty Liver Disease

Interventions

OTHER

Placebo capsules

DRUG

Epeleuton

Trial Locations (16)

Georgia Site 1, Kutaisi

Georgia Site 2, Kutaisi

Georgia Site 3, Tbilisi

Ukraine Site 3, Dnipro

Ukraine Site 1, Kharkiv

Ukraine Site 2, Kyiv

Ukraine Site 4, Kyiv

UK Site 1, Birmingham

UK Site 5, Birmingham

UK Site 6, London

UK Site 7, Norwich

UK Site 3, Oxford

UK Site 4, Plymouth

UK Site 2, Portsmouth

UK Site 9, Belfast

UK Site 8, Liverpool